Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of Baseline Sarcopenia in Determining Acute Toxicity for Head and Neck Cancer Patients Treated with Curative Hadrontherapy: a Prospective Monoinstitutional Study

NCT06207708 is registered in ClinicalTrials.gov with CNAO National Center of Oncological Hadrontherapy as lead sponsor.

NCT NCT06207708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06207708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of Baseline Sarcopenia in Determining Acute Toxicity for Head and Neck Cancer Patients Treated with Curative Hadrontherapy: a Prospective Monoinstitutional Study
Lead sponsor
CNAO National Center of Oncological Hadrontherapy
Phase
Observational
Overall status
Completed
Start date
April 18, 2023
Completion date
January 31, 2025
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer